Synthesis of 6-arylthio analogs of 2′,3′-dideoxy-3′- fluoroguanosine and their effect against hepatitis B virus replication

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 4-6, 2006, Pages 655-665

  Torii, Takayoshi ^a   Onishi, Tomoyuki ^a   Izawa, Kunisuke ^a   Maruyama, Tokumi ^b   Demizu, Yosuke ^b   Neyts, Johan ^c   De Clercq, Erik ^c  

^a AJINOMOTO CO INC   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anti HBV activity; Benzenethiol; FddG analogs

Indexed keywords

2 AMINO 6 CHLORO 9 (2,3 DIDEOXY 3 FUORO BETA DEXTRO ERYTHRO PENTOFURANOSYL)PURINE; 2 AMINO 6 CHLOROPURINE RIBOSIDE; 2 AMINO 9 (2,3 DIDEOXY 3 FLUORO BETA DEXTRO ERYTHRO PENTOFURANOSYL) 6 (4 METHOXYPHENYL)THIOPURINE; 2 AMINO 9 (2,3 DIDEOXY 3 FLUORO BETA DEXTRO ERYTHRO PENTOFURANOSYL) 6 PHENYLTHIOPURINE; 2 AMINO 9 (2,3 DIDEOXY 3 FLUORO BETA DEXTRO ERYTHRO PENTOFURANOSYL)PURINE; 9 (2,3 DIDEOXY 3 FLUORO BETA DEXTRO ERYTHRO PENTOFURANOSYL)GUANINE; ANTIVIRUS AGENT; COMPLEMENTARY DNA; NEBULARINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DIDEOXYNUCLEOSIDES; HEPATITIS B VIRUS; MOLECULAR STRUCTURE; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 33746307895     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600686394     Document Type: Article

References (36)

1. Blair, E.; Darby, G.; Gough, G.; Littler, E.; Rowlands, D.; Tisdale, M. Antiviral Therapy, BIOS Scientific Publishers, Oxford, 100-102, 1998.
2. Fattovich, G.; Brollo, L.; Alberti, A.; Pontisso, P.; Giustina, G.; Realdi, G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hépatology 1988, 8, 1651-1654.
3. Thomas, H.C. Treatment of hepatitis B viral infection. In Viral Hapatitis and Liver Disease, Zuckerman, A.J. Ed.: Alan R. Liss, Inc. New York, 817-822, 1988.
4. Dienstag, J.L.; Schiff, E.R.; Wright, T.L.; Perrillo, R.P.; Hann, H.W.; Goodman, Z.; Crowther, L.; Condreay, L.D.; Woessner, M.; Rubin, M.; Brown, N.A. Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 1999, 341, 1256-1263.
5. Lai, C.L.; Chien, R.N.; Leung, N.W.Y.; Chang, T.T.; Guan, R.; Tai, D.I.; Ng, K.Y.; Wu, P.C.; Dent, J.C.; Barber, J.; Stephenson, S.L.; Gray, D.F. A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998, 339, 61-68.
6. Yokota, T.; Konno, K.; Shigeta, S.; Holy, A.; Balzarini, J.; De Clercq, E. Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HB611 cells. Antiviral Chemistry Chemotherapy 1994, 5, 57-63.
7. Sekiya, K.; Takashima, H.; Ueda, N.; Kamiya, N.; Yuasa, S.; Fujimura, Y.; Ubasawa, M. 2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents. Journal of Medicinal Chemistry 2002, 45, 3138-3142.
8. (a) Hafkemeyer, P.; Keppler-Hafkemeyer, A.; al Haya, M.A.; von Janta-Lipinski, M.; Matthes, E.; Lehmann, C.; Offensperger, W.-B.; Offensperger, S.; Gerok, W.; Blum, H.E. Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxy-3′-fluoroguanosine in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1996, 40, 792-794.
9. (b) Schroder, I.; Holmgren, B.; Oberg, M.; Lofgren, B. Inhibition of human and duck hepatitis B virus by 2′,3′-dideoxy-3′- fluoroguanosine in vitro. Antiviral Research 1998, 37, 57-66.
10. (c) Lofgren, B.; Vickery, K.; Zhang, Y.Y.; Nordenfelt, E. 2′,3′-dideoxy-3′-fluoroguanosine inhibits duck hepatitis B virus in vivo. Journal of Viral Hepatitis 1996, 3, 61-65.
11. (a) Maruyama, T.; Takamatsu, S.; Kozai, S.; Satoh, Y.; Izawa, K. Synthesis of 9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)adenine bearing a selectively removable protecting group. Chemical & Pharmaceutical Bulletin 1999, 47, 966-970.
12. (b) Takamatsu, S.; Maruyama, T.; Katayama, S.; Hirose, N.; Izawa, K. Improved synthesis of 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl) adenine (FddA) using triethylamine trihydrofluoride. Tetrahedron Letters 2001, 42, 2321-2324.
13. (c) Takamatsu, S.; Maruyama, T.; Katayama, S.; Hirose, N.; Naito, M.; Izawa, K. Practical synthesis of 2-(2,3-dideoxy-2-fluoro-β-D-threo- pentofuranosyl)adenine (FddA) via a purine 3′-deoxynucleoside. Tetrahedron Letters 2001, 42, 2325-2328.
14. (d) Takamatsu, S.; Maruyama, T.; Katayama, S.; Hirose, N.; Naito, M.; Izawa, K. Synthesis of 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl) adenine (FddA) via a purine 3-deoxynucleoside. Journal of Organic Chemistry 2001, 66, 7469-7477.
15. (e) Izawa, K.; Takamatsu, S.; Katayama, S.; Hirose, N.; Kozai, S.; Maruyama, T. An industrial process for synthesizing Lodenosine (FddA). Nucleosides, Nucleotides & Nucleic Acids 2003, 22, 507-517.
16. (f) Takamatsu, S.; Maruyama, T.; Izawa, K. Development of and industrial process for synthesizing lodenosine (FddA). Yuki Gosei Kagaku Kyokaishi, 2005, 63, 864-878.
17. (a) Herdewijn, P.; Van Aerschot, A.; Kerremans, L. Synthesis of nucleosides fluorinated in the sugar moiety. Nucleosides & Nucleotides 1989, 8, 65-96.
18. (b) Pankiewicz, K.W. Fluorinated nucleosides. Carbohydrate Research 2000, 327, 87-105.
19. Card, P.J. Synthesis of fluorinated carbohydrates. Journal of Carbohydrate Chemistry 1985, 4, 451-487.
20. (a) Zaitseva, G.V.; Kowollik, G.; Langen, P.; Mikhailopulo, I.A.; Kvasyuk, E.I. Arzneimittel zur Behandlung von Viruserkrankungen. DD Patent 209197, 1984.
21. (b) Burns, C.L.; Koszalka, G.W.; Krenitsky, T.A.; Daluge, S.M. Therapeutic Nucleosides. US Patent 5637574, 1993.
22. (c) Komatsu, H.; Araki, T. Chemo-enzymatic synthesis of 2′,3′-dideoxy-3′-fluoro-β-D-guanosine via 2,3-dideoxy-3-fluoro-α-D-ribose 1-phosphate. Tetrahedron Letters 2003, 44, 2899-2901.
23. (d) Torii, T.; Onishi, T.; Tanji, S.; Izawa, K. Synthesis Study of 3′-α-Fluoro-2′,3′-dideoxyguanosine. Nucleosides, Nucleotides & Nucleic Acids 2005, 24, 1051-1054.
24. Herdewijn, P.; Balzarini, J.; Baba, M.; Pauwels, R.; Van Aerschot, A.; Jannsen, G.; De Clercq, E. Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. Journal of Medicinal Chemistry 1988, 31, 2040-2048.
25. Gerster, J.F.; Jones, J.W.; Robins, R.K. Purine nucleosides. IV. The synthesis of 6-halogenated 9-β-D-ribofuranosylpurines from inosine and guanosine. Journal of Organic Chemistry 1963, 28, 945-948.
26. (a) Von Janta-Lipinski, M.; Gaertner, K.; Schildt, J.; Lehmann, C.; Matthes, E. Preparation of purine nucleosides as antiviral agents. Ger. (East), DD296281, 6 pp, 1991.
27. (b) Matthes, E.; Von Janta-Lipinski, M.; Reimer, K.; Mueller, W.; Meisel, H.; Lehmann, C.; Schildt, J. Preparation of antiviral pyrimidine and purine nucleosides and pharmaceutical compositions containing them. Eur. Pat. Appl., EP409227, 19 pp, 1991.
28. Wagner, D.; Verheyden, J.P.H.; Moffatt, J.G. Preparation and synthetic utility of some organotin derivatives of nucleosides. Journal of Organic Chemistry 1974, 39, 24-30.
29. Liu, Q.-B.; Feng, F.; Qu, G.-R. Deacetylation of 2′-O-Ts-3′, 5′-di-O-acetylpurine nucleosides via a free radical reaction. Journal of Chemical Research 2003, 11, 706-707.
30. Hansske, F.; Robins, M.J. Nucleic acid related compounds. 45. A deoxy-genative [1,2]-hydride shift rearrangement converting cyclic cis-diol monotosylates to inverted secondary alcohols. Journal of the American Chemical Society 1983, 105, 6736-6737.
31. Maruyama, T.; Kozai, S.; Nakamura, K.; Irie, M. Synthesis of 2′-Deoxy-2′-fluoroguanyl-(3′,5′)-guanosine. Nucleosides, Nucleotides & Nucleic Acids 2002, 21, 765-774.
32. Lee, W.W.; Tong, G.L. Synthetic Procedures in Nucleic Acid Chemistry, ed. By Zorbach, W.W.; Tipson, R.S. John Wiley & Sons, New York, 224-227, 1968.
33. (a) Mentel, R.; Kinder, M.; Wegner, U.; Von Janta-Lipinski, M.; Matthes, E. Inhibitory activity of 3′-fluoro-2′ deoxythymidine and related nucleoside analogs against adenoviruses in vitro. Antiviral Research, 1997, 34, 113-119.
34. (b) Matthes, E.; Lehmann, C.; Scholz, D.; Von Janta-Lipinski, M.; Gaertner, K.; Langen, P.; Rosenthal, H.A. Fluorinated nucleosides and method for treating retrovirus infectious therewith. U.S., US4963662, 9 pp, 1990.
35. (c) Matthes, E.; Lehmann, C.; Scholz, D.; Von Janta-Lipinski, M.; Gaertner, K.; Langen, P.; Rosenthal, H.A. Preparation and testing of fluorinated nucleosides for treatment of acquired immune deficiency syndrome (AIDS). Eur. Pat. Appl. EP254268, 13 pp, 1988.
36. Blumberg, B.S.; Riddell, N.M. Inherited antigenic differences in human serum beta lipoproteins. A second antiserum. The Journal of Clinical Investigation, 1963, 42, 867-875.